No Data
No Data
FOSUN PHARMA: ANNUAL REPORT 2024
Earnings Preview: FOSUN PHARMA to Report Financial Results on April 29
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
Hong Kong stocks movement | HENLIUS (02696) rises again by over 9% as FOSUN PHARMA plans to increase its shareholding of HENLIUS by 3.87% for 0.517 billion HKD.
HENLIUS (02696) rose more than 9% again, as of the time of writing, it increased by 8.54%, reaching 36.85 Hong Kong dollars, with a transaction amount of 35.2823 million Hong Kong dollars.
After the unsuccessful privatization of HENLIUS, FOSUN PHARMA took action to increase its Shareholding. Is it continuing to send Bullish signals? | Quick read of the announcement.
① After the privatization failure last year, FOSUN PHARMA continues to signal its bullish outlook on HENLIUS, and today increased its shareholding in HENLIUS; ② HENLIUS had impressive performance last year, and recently has been actively releasing positive news.
Express News | Fosun International - Henlink Agreed to Sell 14.9 Mln Unlisted Shares of Henlius to Fosun Pharma Industrial at HKD24.6 per Share